VIRI

Virios Therapeutics, Inc. [VIRI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

VIRI Stock Summary

In the News

11:21 29 Mar 2024 VIRI

Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript

Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Greg Duncan - CEO Angela Walsh - SVP, Finance & Treasurer Mike Gendreau - CMO Conference Call Participants David Bautz - Zacks Small Cap Research Sean Lee - H.C. Wainwright Operator Good day, and welcome to the Virios Therapeutics, Inc. Third Quarter 2023 Earnings Update.

07:05 29 Mar 2024 VIRI

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, announced today that it will report third quarter 2023 financial results on Monday, November 13, 2023 before the open of the financial markets. Management will also host a webcast and conference call on November 13, 2023 at 8:30 a.m. ET to discuss the results and provide a corporate update.

07:05 29 Mar 2024 VIRI

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the annual ThinkEquity Conference on Thursday, October 19, 2023 at 11:00 am ET in New York, NY.

07:05 29 Mar 2024 VIRI

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors on Monday, September 18, 2023, at 11:00 am ET.

10:05 29 Mar 2024 VIRI

Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call Transcript

Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Angela Walsh - Senior Vice President, Finance & Treasurer Greg Duncan - Chief Executive Officer Mike Gendreau - Chief Medical Officer Conference Call Participants David Bautz - Zacks Small Cap Research Sean Lee - H.C. Wainwright Operator Good day, and welcome to the Virios Therapeutics, Inc. Q2 2023 Earnings Update.

07:49 29 Mar 2024 VIRI

VIRI Stock Earnings: Virios Beats EPS Estimates

Virios Therapeutics (NASDAQ: VIRI ) reported first quarter results for 2023. Virios reported a loss per share of 8 cents.

07:05 29 Mar 2024 VIRI

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

ATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023 before the open of the financial markets.

11:30 29 Mar 2024 VIRI

Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal

Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune response-triggered maladies. The company went public in December 2020.

10:48 29 Mar 2024 VIRI

Virios Therapeutics stock doubles as fibromyalgia program moves forward

Virios Therapeutics shares more than doubled after the biotechnology company announced that its proposed Phase 3 program featuring its lead development candidate IMC-1 for fibromyalgia has been considered acceptable based on initial feedback from the US Food and Drug Administration (FDA). IMC-1 is a novel, fixed-dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the company's end goal being the reduction of virally promoted fibromyalgia disease symptoms.

08:01 29 Mar 2024 VIRI

Why Is Virios Therapeutics (VIRI) Stock Up 92% Today?

Virios Therapeutics (NASDAQ: VIRI ) stock is rocketing higher on Tuesday following an update on its planned Phase 3 clinical trial of IMC-1. IMC-1 is Virios Therapeutics' lead drug candidate in development for the treatment of herpes virus replication.

VIRI Financial details

Company Rating
Sell
Market Cap
8.81M
Income
-5.26M
Revenue
0
Book val./share
0.2
Cash/share
0.17
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
29 Feb 2024
P/E
-2.15
Forward P/E
-1.6
PEG
0.29
P/S
-
P/B
2.78
P/C
2.82
P/FCF
-2.2
Quick Ratio
9.82
Current Ratio
10.77
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.28
EPS next Y
-0.3
EPS next Q
-0.04
EPS this Y
-74.55%
EPS next Y
6.84%
EPS next 5Y
-121.37%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-11.44%
-
-
-
-
SMA20
10.81%
SMA50
-42.25%
SMA100
-28.07%
Inst Own
3.53%
Inst Trans
0.91%
ROA
-118%
ROE
-109%
ROC
-1.34%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
19.26M
Shs Float
14.86M
-
-
-
-
Target Price
-
52W Range
0.279-2.42
52W High
-
52W Low
-
RSI
61.44
Rel Volume
1.57
Avg Volume
263.24K
Volume
414.21K
Perf Week
35.34%
Perf Month
24.12%
Perf Quarter
-37.39%
Perf Half Y
-49.03%
-
-
-
-
Beta
1.826
-
-
Volatility
0.06%, 0.05%
Prev Close
-0.95%
Price
0.4791
Change
8.64%

VIRI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.57-2.1-1.92-1.1-0.28
Operating cash flow per share
-0.43-0.79-1.88-1.04-0.26
Free cash flow per share
-0.43-0.79-1.88-1.04-0.26
Cash per share
0.066.051.680.640.18
Book value per share
-1.026.081.740.660.2
Tangible book value per share
-1.026.081.740.660.2
Share holders equity per share
-1.026.081.740.660.2
Interest debt per share
0.810.080-0.010
Market cap
80.75M37M42.65M2.61M10.8M
Enterprise value
84.08M7.21M28.64M-4.42M7.48M
P/E ratio
-29.17-3.58-2.67-0.21-2.04
Price to sales ratio
00000
POCF ratio
-38.6-9.5-2.72-0.23-2.22
PFCF ratio
-38.6-9.5-2.72-0.23-2.22
P/B Ratio
-16.341.242.940.362.84
PTB ratio
-16.341.242.940.362.84
EV to sales
00000
Enterprise value over EBITDA
-38.59-0.72-1.830.36-1.37
EV to operating cash flow
-40.19-1.85-1.830.39-1.54
EV to free cash flow
-40.19-1.85-1.830.39-1.54
Earnings yield
-0.03-0.28-0.37-4.66-0.49
Free cash flow yield
-0.03-0.11-0.37-4.39-0.45
Debt to equity
-0.740000
Debt to assets
11.510000
Net debt to EBITDA
-1.532.980.90.570.61
Current ratio
0.1920.5512.378.0211.62
Interest coverage
-7.38-26.04-2.76K182.520
Income quality
0.850.380.980.940.92
Dividend Yield
00000
Payout ratio
0-0.01000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
3.6316.948.664.051.13
ROIC
1.87-0.33-1.08-1.67-1.43
Return on tangible assets
-8.76-0.33-1.01-1.46-1.27
Graham Net
-1.025.741.530.540.16
Working capital
-1.3M29.94M14.5M7.33M3.81M
Tangible asset value
-4.94M29.94M14.5M7.33M3.81M
Net current asset value
-4.94M29.94M14.5M7.33M3.81M
Invested capital
-0.740000
Average receivables
559.5554.516200
Average payables
90.54K202.16K361.38K463.51K342.54K
Average inventory
-392.5-554.5-16200
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0.56-0.35-1.1-1.66-1.39
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q3

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.11-0.08-0.08-0.06-0.06
Operating cash flow per share
-0.15-0.09-0.04-0.05-0.08
Free cash flow per share
-0.15-0.09-0.04-0.05-0.08
Cash per share
0.380.290.250.250.17
Book value per share
0.40.330.250.250.2
Tangible book value per share
0.40.330.250.250.2
Share holders equity per share
0.40.330.250.250.2
Interest debt per share
00000
Market cap
4.33M6.75M25.41M17.66M11.07M
Enterprise value
-2.71M1.41M20.82M12.87M7.76M
P/E ratio
-0.53-1.14-4.41-3.57-2.51
Price to sales ratio
00000
POCF ratio
-1.62-3.97-34.22-18.38-7.54
PFCF ratio
-1.62-3.97-34.22-18.38-7.54
P/B Ratio
0.591.135.423.712.91
PTB ratio
0.591.135.423.712.91
EV to sales
00000
Enterprise value over EBITDA
1.29-0.91-14.09-10.1-6.82
EV to operating cash flow
1.01-0.83-28.04-13.4-5.28
EV to free cash flow
1.01-0.83-28.04-13.4-5.28
Earnings yield
-0.47-0.22-0.06-0.07-0.1
Free cash flow yield
-0.62-0.25-0.03-0.05-0.13
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
3.363.423.113.762.91
Current ratio
8.029.718.8310.7711.62
Interest coverage
93.6538.5200-28.16
Income quality
1.311.120.520.781.33
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
10.770.670.60.5
ROIC
-0.28-0.25-0.31-0.27-0.31
Return on tangible assets
-0.24-0.23-0.28-0.24-0.26
Graham Net
0.330.260.220.230.15
Working capital
7.33M4.78M4.07M4.76M3.81M
Tangible asset value
7.33M5.97M4.69M4.76M3.81M
Net current asset value
7.33M4.78M4.07M4.76M3.81M
Invested capital
00000
Average receivables
00000
Average payables
626.29K354.13K174.7K209.84K158.64K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.28-0.25-0.31-0.26-0.29
Capex per share
00000

VIRI Frequently Asked Questions

What is Virios Therapeutics, Inc. stock symbol ?

Virios Therapeutics, Inc. is a US stock , located in Alpharetta of Ga and trading under the symbol VIRI

What is Virios Therapeutics, Inc. stock quote today ?

Virios Therapeutics, Inc. stock price is $0.4791 today.

Is Virios Therapeutics, Inc. stock public?

Yes, Virios Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Price Range
Similar Market Cap